Investigational drug · Phase 2
FB825
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Allergic Asthma, Atopic Dermatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "FB825"
First trial start
2021
Jul 27, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FB825", any sponsor or status.
Conditions studied
As listed on its trial records.
- Allergic Asthma
- Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Asthma · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "FB825" as an intervention, largest first.
- Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Oneness Biotech Co., Ltd.Industry
NCT06397911 · 114 participants (planned) · Start Aug 8, 2024 · Primary completion May 31, 2027
Drug: FB825; Placebo · For: Atopic Dermatitis
Sites: Fountain Valley, California; Fremont, California; Los Angeles, California · 16 sites in all
- Evaluate the Efficacy and Safety of FB825 in Adult With Allergic AsthmaPivotal-lookingRecruiting
Oneness Biotech Co., Ltd.Industry
NCT05008965 · 100 participants (planned) · Start Jul 27, 2021 · Primary completion Dec 2027
Drug: FB825; Placebo · For: Allergic Asthma
Sites: Kaohsiung City, Taiwan; New Taipei City, Taiwan; Taichung, Taiwan · 13 sites in all
Oneness Biotech Co., Ltd.Industry
NCT04413942 · 99 participants · Start Mar 10, 2020 · Primary completion Dec 31, 2021
Drug: FB825 · For: Atopic Dermatitis
Sites: Beverly Hills, California; Encino, California; Huntington Beach, California · 18 sites in all
Fountain Biopharma Inc.Industry
NCT02309762 · 54 participants · Start Mar 2015 · Primary completion Feb 2016
Drug: FB825; Placebo · For: Healthy
- A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy AdultsStatus unknown
Oneness Biotech Co., Ltd.Industry
NCT05952986 · 22 participants · Start May 3, 2023 · Primary completion Mar 26, 2024
Drug: FB825 or Placebo in subcutaneous route; FB825 in intravenous route · For: Atopic Dermatitis
Sites: Anaheim, California
Oneness Biotech Co., Ltd.Industry
NCT05059509 · 20 participants · Start Feb 6, 2020 · Primary completion May 10, 2021
Drug: FB825 · For: Atopic Dermatitis
Sites: Taipei, Taiwan
Fountain Biopharma Inc.Industry
NCT03758716 · 12 participants · Start Jul 3, 2017 · Primary completion Jan 28, 2019
Drug: FB825, FB825-15D11, Anti-CemX · For: Atopic Dermatitis
Sites: Taipei, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Allergic Asthma
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
- JYB1904RPT904, ozureprubartPhase 35 trials
Jemincare · Chronic Spontaneous Urticaria, Perennial Allergic Rhinitis, Immune System Diseases
- 000 MM09Phase 32 trials
Inmunotek S.L. · Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- EP-088_MM09Phase 32 trials
Inmunotek S.L. · Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.